Industry Insights

  1. How A Strategic Bioanalysis CRO Partnership Empowers Sponsors 1/8/2026

    Choosing the right bioanalysis CRO is vital to avoid costly delays. Sponsors need evaluation strategies that prioritize proven quality, predictable timelines, and submission-ready data.

  2. How Should Scientific Focus Change In 2026? Researchers Weigh In 1/8/2026

    To kick off 2026, clinical researchers share how they think research should change in the new year.

  3. 6 Key Implications Of EU Clinical Trials Regulation 1/7/2026

    Centralized submissions, greater transparency, and stronger patient protections reshape EU clinical trials, impacting timelines, costs, and strategies for sponsors and CROs.

  4. Researchers Want A Design Shake-Up In 2026 1/7/2026

    When asked what clinical research professionals should leave behind in 2025, quite a few lamented the stale, even problematic, approach to clinical trial design. Here's what they want done differently in 2026.

  5. Meeting Your Clinical Trial Enrollment Target Without Delays 1/6/2026

    Bridge the enrollment gap by blending site-based tactics with global direct-to-patient outreach. Use digital screening and EMR intelligence to ensure faster, more predictable paths to randomization.

  6. Solving Trial Enrollment Challenges With Direct-To-Patient Recruitment 1/6/2026

    Overcome enrollment bottlenecks by shifting from site-centric models to tech-enabled, direct-to-patient outreach.

  7. How Rescue Studies Use Direct-To-Patient Strategies To Accelerate Clinical Trial Enrollment 1/6/2026

    If your trial struggles to overcome enrollment bottlenecks, a tech-enabled rescue strategy could be the solution.

  8. Why We Need To Look To The Future Of Clinical Trials 1/6/2026

    Explore how decentralized trial elements, community-focused site networks, and patient-centric infrastructure can improve recruitment, data quality, equity, and efficiency.

  9. How DCTs Can Shift The Pediatric Rare Disease Research Landscape 1/6/2026

    DCT solutions are not just about bringing the trial to the patient’s home and reducing logistical burdens, but also strengthening the family-researcher connection.

  10. Psychiatric Drug Development Renaissance: With Familiar Risks 1/6/2026

    Emerging psychiatric therapies bring hope, but progress is fragile. Biomarker-driven, mechanism-first approaches help overcome biological, regulatory, and commercial barriers.